…
Nu Skin Enterprises, Inc., together with its subsidiaries, develops and distributes various beauty and wellness products worldwide. It offers skin care devices, cosmetics, and other personal care products, including ageLOC LumiSpa and ageLOC LumiSpa iO, ageLOC Body Spa; and nutricentials skin care products. The company also provides wellness products, such as ageLOC Meta, LifePak nutritional supplements, ageLOC TR90 weight management system, and Beauty Focus Collagen+. In addition, it is involved in the research and product development of skin care products and nutritional supplements. The company sells its products under the Nu Skin, Pharmanex, and ageLOC brands through retail stores, website, digital platforms, and independent direct sellers and marketers, as well as a service center. Nu Skin Enterprises, Inc. was founded in 1984 and is headquartered in Provo, Utah.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Nu Skin Enterprises is a global personal care and wellness company that develops and sells skincare, anti-aging and nutritional products primarily through an independent distributor network. Long-term growth drivers include product innovation in anti-aging and wellness, expansion in international and digital channels, and recurring revenue from consumable products which may support steady cash flows. Investors may find the company attractive for its established brand recognition and scalable distribution footprint.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 88.97M | 232.46M | 256.23M | 255.17M | 219.67M |
| Net income | 104.78M | 147.27M | 191.35M | 173.55M | 121.89M |
| Selling general administrative | 555.77M | 666.39M | 646.85M | 615.97M | 662.30M |
| Selling and marketing expenses | 879.63M | 1068.19M | 1019.49M | 955.60M | 1071.02M |
| Gross profit | 1594.74M | 2020.45M | 1923.91M | 1839.00M | 2044.87M |
| Reconciled depreciation | 72.51M | 76.32M | 73.99M | 76.65M | 83.00M |
| Ebit | 110.85M | 233.99M | 257.56M | 190.78M | 219.67M |
| Ebitda | 207.84M | 337.73M | 331.56M | 267.43M | 302.67M |
| Depreciation and amortization | 96.99M | 103.74M | 73.99M | 76.65M | 83.00M |
| Non operating income net other | -21.88M | -1.53M | -1.33M | -12.25M | -21.19M |
| Operating income | 110.85M | 233.99M | 257.56M | 190.78M | 240.86M |
| Other operating expenses | 2066.32M | 2409.81M | 2324.37M | 2152.99M | 2367.46M |
| Interest expense | 21.88M | 28.95M | 1.33M | 64.40M | 0.00M |
| Tax provision | -15.81M | 85.19M | 64.88M | 81.62M | 97.78M |
| Interest income | 13.50M | 11.00M | 13.10M | 19.20M | 21.80M |
| Non recurring | 48.49M | 51.87M | - | - | 70.69M |
| Income tax expense | -15.81M | 85.19M | 64.88M | 81.62M | 97.78M |
| Total revenue | 2225.66M | 2695.67M | 2581.93M | 2420.42M | 2679.01M |
| Total operating expenses | 1435.40M | 1734.58M | 1666.34M | 1571.57M | 1733.32M |
| Cost of revenue | 630.91M | 675.22M | 658.03M | 581.42M | 634.14M |
| Total other income expense net | -21.88M | -1.53M | -1.33M | 64.40M | -21.19M |
| Net income from continuing ops | 104.78M | 147.27M | 191.35M | 173.55M | 121.89M |
| Net income applicable to common shares | 104.78M | 147.27M | 191.35M | 173.55M | 121.89M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 1820.97M | 1906.48M | 1957.08M | 1769.01M | 1694.45M |
| Intangible assets | 66.70M | 76.99M | 89.53M | 80.32M | 89.99M |
| Other current assets | 87.82M | 76.91M | 14.73M | 69.85M | 51.88M |
| Total liab | 923.67M | 993.71M | 1062.81M | 893.72M | 912.58M |
| Total stockholder equity | 897.30M | 912.77M | 894.27M | 875.29M | 781.87M |
| Other current liab | 253.23M | 339.06M | 366.65M | 270.12M | 302.48M |
| Common stock | 0.09M | 0.09M | 0.09M | 0.09M | 0.09M |
| Capital stock | 0.09M | 0.09M | 0.09M | 0.09M | 0.09M |
| Retained earnings | 1939.50M | 1911.73M | 1840.74M | 1727.77M | 1635.75M |
| Other liab | 98.28M | 106.47M | 102.28M | 96.80M | 111.92M |
| Good will | 206.43M | 206.43M | 202.98M | 196.57M | 196.57M |
| Other assets | 244.43M | 175.46M | 293.19M | 154.02M | 144.11M |
| Cash | 264.73M | 339.59M | 402.68M | 335.63M | 386.91M |
| Cash and equivalents | 264.73M | 339.59M | 402.68M | 335.63M | 386.91M |
| Total current liabilities | 359.24M | 529.69M | 542.86M | 356.76M | 439.65M |
| Current deferred revenue | 27.05M | 33.14M | 35.05M | 20.16M | 20.10M |
| Net debt | 214.28M | 125.45M | 97.69M | 132.03M | 43.55M |
| Short term debt | 25.00M | 107.50M | 74.98M | 27.50M | 69.45M |
| Short long term debt | 25.00M | 107.50M | 30.00M | 27.50M | 69.45M |
| Short long term debt total | 479.01M | 465.04M | 500.38M | 467.66M | 430.46M |
| Other stockholder equity | -955.78M | -925.16M | -881.79M | -767.28M | -774.04M |
| Property plant equipment | 444.81M | 453.67M | 468.18M | 453.60M | 464.54M |
| Total current assets | 759.87M | 872.95M | 903.20M | 740.17M | 799.24M |
| Long term investments | 39.49M | 35.87M | - | - | - |
| Net tangible assets | 897.30M | 912.77M | 894.27M | 875.29M | 781.87M |
| Short term investments | 13.78M | 15.22M | 21.22M | 8.41M | 11.35M |
| Net receivables | 47.36M | 41.30M | 63.37M | 50.38M | 53.28M |
| Long term debt | 377.47M | 268.78M | 305.39M | 334.46M | 361.01M |
| Inventory | 346.18M | 399.93M | 314.37M | 275.89M | 295.82M |
| Accounts payable | 53.96M | 49.99M | 66.17M | 38.98M | 47.62M |
| Accumulated other comprehensive income | -86.51M | -73.90M | -64.77M | -85.29M | -79.93M |
| Common stock total equity | 0.09M | 0.09M | 0.09M | 0.09M | 0.09M |
| Retained earnings total equity | 1939.50M | 1911.73M | 1840.74M | 1727.77M | 1635.75M |
| Treasury stock | - | -1526.86M | -1461.59M | -1324.83M | -1326.61M |
| Non currrent assets other | 115.17M | 113.11M | 72.50M | 154.02M | 144.11M |
| Non current assets total | 1061.10M | 1033.53M | 1053.88M | 1028.84M | 895.21M |
| Capital lease obligations | 76.54M | 127.50M | 164.98M | 145.05M | - |
| Long term debt total | 389.61M | 274.10M | 313.12M | 334.46M | 361.01M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -8.02M | -1.15M | -0.66M | 2.73M | 0.12M |
| Change to liabilities | -127.40M | -113.86M | 126.68M | -69.08M | -27.41M |
| Total cashflows from investing activities | -67.08M | -88.73M | -79.43M | -71.41M | -108.76M |
| Net borrowings | 22.42M | 40.00M | -27.50M | -69.45M | 22.66M |
| Total cash from financing activities | -99.50M | -104.70M | -245.17M | -154.79M | -116.71M |
| Change to operating activities | -130.80M | -105.24M | 70.07M | -146.44M | -18.90M |
| Net income | 104.78M | 147.27M | 191.35M | 173.55M | 121.89M |
| Change in cash | -74.87M | -63.09M | 67.05M | -51.28M | -39.49M |
| Begin period cash flow | 339.59M | 402.68M | 335.63M | 386.91M | 426.40M |
| End period cash flow | 264.73M | 339.59M | 402.68M | 335.63M | 386.91M |
| Total cash from operating activities | 108.06M | 141.58M | 379.14M | 177.93M | 202.74M |
| Depreciation | 72.51M | 76.32M | 73.99M | 76.65M | 83.00M |
| Other cashflows from investing activities | -8.02M | -18.96M | -14.95M | -8.07M | -38.51M |
| Dividends paid | 77.02M | 76.27M | 78.39M | 82.19M | 80.58M |
| Change to inventory | 40.31M | -95.32M | -31.14M | 18.45M | -33.37M |
| Change to account receivables | -11.45M | 20.22M | -11.21M | 2.75M | -10.45M |
| Sale purchase of stock | -70.05M | -80.42M | -144.33M | -0.82M | -69.56M |
| Other cashflows from financing activities | 481.98M | 168.86M | 120.76M | 142.68M | -7.24M |
| Change to netincome | -21.07M | 80.99M | 15.07M | 15.70M | 69.73M |
| Capital expenditures | 59.06M | 68.61M | 63.82M | 66.07M | 70.37M |
| Change receivables | -11.45M | 20.22M | -11.21M | 2.75M | -10.45M |
| Cash flows other operating | 50.38M | 25.97M | 14.39M | -40.08M | -0.65M |
| Exchange rate changes | - | -11.24M | 12.51M | -3.01M | -16.75M |
| Cash and cash equivalents changes | -58.52M | -63.09M | 67.05M | -51.28M | -39.49M |
| Change in working capital | -92.67M | -193.62M | 52.56M | -132.44M | -71.88M |
| Stock based compensation | 12.37M | 23.19M | 24.06M | 9.91M | 26.61M |
| Other non cash items | 62.71M | 82.60M | 49.09M | 48.29M | 58.05M |
| Free cash flow | 49.01M | 72.97M | 315.32M | 111.86M | 132.37M |
Sector: Consumer Defensive Industry: Household & Personal Products
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| NUS Nu Skin Enterprises Inc |
- -% |
3.89 | 16.67 | - | 0.48 | 1.16 | 0.64 | 8.03 |
| PG Procter & Gamble Company |
-0.99 0.59% |
167.67 | 23.58 | 22.62 | 4.07 | 7.24 | 4.40 | 16.08 |
| LRLCF L'Oréal S.A |
- -% |
497.60 | 41.14 | 34.25 | 6.52 | 8.59 | 6.67 | 27.76 |
| LRLCY L’Oreal Co ADR |
-0.27 0.27% |
99.39 | 32.44 | 25.64 | 5.16 | 6.03 | 4.79 | 19.51 |
| UL Unilever PLC ADR |
-0.69 1.04% |
65.78 | 21.53 | 16.39 | 2.66 | 7.29 | 2.77 | 12.45 |
Nu Skin Enterprises, Inc., together with its subsidiaries, develops and distributes various beauty and wellness products worldwide. It offers skin care devices, cosmetics, and other personal care products, including ageLOC LumiSpa and ageLOC LumiSpa iO, ageLOC Body Spa; and nutricentials skin care products. The company also provides wellness products, such as ageLOC Meta, LifePak nutritional supplements, ageLOC TR90 weight management system, and Beauty Focus Collagen+. In addition, it is involved in the research and product development of skin care products and nutritional supplements. The company sells its products under the Nu Skin, Pharmanex, and ageLOC brands through retail stores, website, digital platforms, and independent direct sellers and marketers, as well as a service center. Nu Skin Enterprises, Inc. was founded in 1984 and is headquartered in Provo, Utah.
| Name | Title | Year Born |
|---|---|---|
| Mr. Steven J. Lund | Exec. Chairman | 1953 |
| Mr. Ryan S. Napierski | Pres, CEO & Director | 1974 |
| Mr. Mark H. Lawrence | Exec. VP & CFO | 1970 |
| Dr. Joseph Y. Chang Ph.D. | Exec. VP & Chief Scientific Officer | 1953 |
| Mr. Chayce David Clark | Exec. VP & Gen. Counsel | 1983 |
| Mr. Ritch N. Wood | Exec. Advisor | 1966 |
| Mr. D. Matthew Dorny | Legal Advisor | 1964 |
| Ms. Mang Yee Tang | Exec. VP and Chief Global Growth & Customer Experience Officer | 1971 |
| Mr. Blake M. Roney | Founder | 1959 |
| Ms. Sandra N. Tillotson | Founder | 1957 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.